Lv31
300 积分 2024-02-22 加入
The principles and utilization of ETDRS chart and the comparison with Snellen chart
2个月前
已完结
New Visual Acuity Charts for Clinical Research
2个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
2个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
2个月前
已完结
The WRN helicase: resolving a new target in microsatellite unstable cancers
2个月前
已完结
中国干眼专家共识：定义和分类（2020年）
3个月前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
5个月前
已完结
皖公网安备34019202002308
